Hypoxia-activated prodrugs for cancer
This article was originally published in Start Up
Cancers, even those that initially respond to treatment, can become resistant to chemotherapy and radiotherapy; one of the causes behind this is the hypoxia found in some tumors. OncoTherics Ltd. is tackling this by developing non-toxic prodrugs that are activated to potent anticancer drugs in hypoxic conditions, selectively targeting the hard-to-treat cancer cells but sparing healthy tissue.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.